Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HG69 | ISIN: GB00B0LCW083 | Ticker-Symbol: H5P
Tradegate
04.07.25 | 12:50
22,800 Euro
-0,87 % -0,200
1-Jahres-Chart
HIKMA PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
HIKMA PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
22,80023,40009:46
23,00023,20009:43

Aktuelle News zur HIKMA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrFDA approves Hikma's Tyzavan for multiple infections3
HIKMA PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiHikma Gets FDA Approval For TYZAVAN Vancomycin Injection222LONDON (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK) Wednesday said that the US Food and Drug Administration (FDA) has approved TYZAVAN, a ready-to-infuse formulation of vancomycin.TYZAVAN is...
► Artikel lesen
MiHikma Pharmaceuticals USA Inc.: Hikma receives FDA approval for TYZAVAN (Vancomycin Injection, USP) in the US87Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational...
► Artikel lesen
30.06.Hikma to splash $1B on US production and R&D, joining branded drugmakers' investment spree4
30.06.Hikma Pharmaceuticals to Invest $1B in U.S. Manufacturing & R&D Capabilities2
30.06.Generic drugmaker Hikma pledges $1bn in US investment1
30.06.Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D3
10.06.DIRECTOR DEALINGS: Hikma exec and AB Dynamics advisor sell shares5
09.06.Hikma Pharmaceutical - Director/PDMR Shareholding5
05.06.Hikma Pharmaceutical - Director/PDMR Shareholding2
03.06.Hikma Pharmaceutical - Director/PDMR Shareholding2
29.05.Hikma Pharmaceutical - Fitch upgrades Hikma to 'BBB'2
28.05.Fitch upgrades Hikma Pharmaceuticals to 'BBB' with stable outlook4
28.05.Fitch stuft Hikma Pharmaceuticals auf 'BBB' hoch mit stabilem Ausblick4
27.05.Bio-Thera Solutions And Hikma Pharma Say FDA Approved STARJEMZA Injection396LONDON (dpa-AFX) - Bio-Thera Solutions Ltd and Hikma Pharmaceuticals PLC announced that the U.S. Food and Drug Administration has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar...
► Artikel lesen
27.05.Hikma Pharmaceuticals USA Inc.: Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing STELARA (ustekinumab) Injection340GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...
► Artikel lesen
20.05.Hikma Pharmaceutical - Director/PDMR Shareholding1
20.05.Broker tips: Kingfisher, Accesso, Hikma5
20.05.RBC Capital ups price target on Hikma6
20.05.RBC lifts Hikma stock target on Rx and Injectables optimism2
Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1